Anteris Technologies Ltd.


Anteris Technologies is dedicated to revolutionizing cardiac care by developing innovative, science-driven solutions that restore healthy heart function. Their focus is on disrupting heart valve disease through cutting-edge, biomimetic transcatheter heart valves designed to mimic native heart physiology.

Industries

biotechnology
health-care
medical

Nr. of Employees

medium (51-250)

Anteris Technologies Ltd.

860 Blue Gentian Road, Suite 340, Eagan MN 55121, United States


Products

Biomimetic transcatheter heart valve system

A transcatheter aortic valve system using a single-piece, native-shaped biomimetic valve geometry combined with treated biological tissue designed to resist calcification and a balloon-expandable delivery platform for transcatheter implantation.


Services

Design and execution of first-in-human and early feasibility clinical studies for implantable transcatheter heart valves, including imaging follow-up and one-year outcome assessment.

Support for animal studies and preclinical evaluation of novel structural heart devices and repair systems.

Preparation of investor presentations, periodic SEC/ASX filings, press releases and coordination with analysts and transfer agents.

Expertise Areas

  • Transcatheter aortic valve replacement (TAVR) device development
  • Biomaterials and anti-calcification tissue engineering
  • Clinical trial design and execution (FIH, EFS)
  • Cardiac imaging and 4D flow CMR analysis
  • Show More (4)

Key Technologies

  • Biomimetic valve design
  • Anti-calcification tissue treatment
  • Balloon-expandable catheter delivery
  • 4D flow cardiac MRI (4D Flow CMR)
  • Show More (4)

News & Updates

Annual General Meeting 2024

The recording of the Annual General Meeting including strategic updates and future plans.

DurAVR® THV Clinical Data Update at Sydney Valves

Data demonstrating favorable hemodynamic profile and zero prosthesis-patient mismatch in small annuli patients.

MRI Data Update on First-in-Human Study at London Valves

Cardiac MRI analyses comparing flow dynamics and LV function between DurAVR® THV recipients and healthy controls.

TCT 2024 Physician Panel Interview

Discussion on MRI flow & LV mass data, impact of valve design on flow, and disease regression.

New York Valves 2024 Symposium

Experts discuss the biomimetic design of DurAVR® THV and its impact on hemodynamics and blood flow.

Update on DurAVR® THV Valve-in-Valve Experience

Restoration of hemodynamic performance in complex valve-in-valve cases.

View All News

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.